• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

When to publish measures of disproportionality derived from spontaneous reporting databases?

作者信息

de Boer Anthonius

机构信息

Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht, The Netherlands.

出版信息

Br J Clin Pharmacol. 2011 Dec;72(6):909-11. doi: 10.1111/j.1365-2125.2011.04087.x.

DOI:10.1111/j.1365-2125.2011.04087.x
PMID:21848575
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3244637/
Abstract
摘要

相似文献

1
When to publish measures of disproportionality derived from spontaneous reporting databases?何时公布源自自发报告数据库的不成比例性衡量指标？
Br J Clin Pharmacol. 2011 Dec;72(6):909-11. doi: 10.1111/j.1365-2125.2011.04087.x.
2
Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database.药物警戒数据库中用于识别药物不良反应的不成比例性分析的益处与优势。
Br J Clin Pharmacol. 2011 Dec;72(6):905-8. doi: 10.1111/j.1365-2125.2011.04037.x.
3
A comparison of disproportionality analysis methods in national adverse drug reaction databases of China.中国国家药品不良反应数据库中不成比例分析方法的比较
Expert Opin Drug Saf. 2014 Jul;13(7):853-7. doi: 10.1517/14740338.2014.915938. Epub 2014 Jun 11.
4
Exploration of statistical shrinkage parameters of disproportionality methods in spontaneous reporting system of China.中国自发呈报系统中不成比例法统计收缩参数的探索
Pharmacoepidemiol Drug Saf. 2015 Sep;24(9):962-70. doi: 10.1002/pds.3811. Epub 2015 Jun 11.
5
Detection of cluster adverse drug events in the spontaneous reporting system of China using a disproportionality filter algorithm.利用不相称性过滤算法在中国自发报告系统中检测簇状不良药物事件。
J Clin Pharm Ther. 2019 Dec;44(6):952-957. doi: 10.1111/jcpt.13021. Epub 2019 Aug 13.
6
Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases.评估不均衡性分析的掩盖效应在两个自发报告系统数据库中的程度及影响。
Pharmacoepidemiol Drug Saf. 2014 Feb;23(2):195-207. doi: 10.1002/pds.3529. Epub 2013 Nov 15.
7
Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?基于上市后病例报告的不均衡分析可否用于比较药物安全性特征？
Clin Drug Investig. 2017 May;37(5):415-422. doi: 10.1007/s40261-017-0503-6.
8
Safety Meta-Analysis: A Call for Appropriate Use of Disproportionality Measures From Spontaneous Reporting Systems.安全性荟萃分析：呼吁合理使用来自自发报告系统的不成比例性测量方法。
J Am Coll Cardiol. 2016 May 10;67(18):2193. doi: 10.1016/j.jacc.2016.01.082.
9
Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: A subgroup approach to disproportionality analysis.越南自发药物不良反应数据库中药物性史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症：不成比例分析的亚组方法
J Clin Pharm Ther. 2019 Feb;44(1):69-77. doi: 10.1111/jcpt.12754. Epub 2018 Aug 20.
10
Comparison of statistical signal detection methods within and across spontaneous reporting databases.自发报告数据库内部及之间统计信号检测方法的比较。
Drug Saf. 2015 Jun;38(6):577-87. doi: 10.1007/s40264-015-0289-5.

引用本文的文献

1
A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS).多发性硬化症中与疾病修正疗法相关的神经系统不良事件的不成比例分析：来自美国食品药品监督管理局不良事件报告系统（FAERS）的见解
J Neurol. 2025 Jun 4;272(6):445. doi: 10.1007/s00415-025-13189-8.
2
FDA Adverse Event Reporting System (FAERS) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERS.美国食品药品监督管理局不良事件报告系统（FAERS）要点：解读、应用及阐释向FAERS报告的不良事件数据指南
Clin Pharmacol Ther. 2025 Sep;118(3):567-582. doi: 10.1002/cpt.3701. Epub 2025 May 19.
3
Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases.吡非尼酮和尼达尼布的上市后安全性问题：对来自美国食品药品监督管理局不良事件报告系统数据库和日本药品不良事件报告数据库的个体病例安全报告的分析
Front Pharmacol. 2025 Apr 28;16:1530697. doi: 10.3389/fphar.2025.1530697. eCollection 2025.
4
Post-marketing safety profile of ganirelix in women: a 20-year pharmacovigilance analysis of global adverse drug event databases (2004-2024).加尼瑞克在女性中的上市后安全性概况：对全球药品不良事件数据库（2004 - 2024年）的20年药物警戒分析
BMC Pharmacol Toxicol. 2025 Apr 22;26(1):91. doi: 10.1186/s40360-025-00920-4.
5
Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system.依列卡福妥/替扎卡福妥/依伐卡托的真实世界安全性概况：使用美国食品药品监督管理局不良事件报告系统的不成比例性分析
Front Pharmacol. 2025 Mar 12;16:1531514. doi: 10.3389/fphar.2025.1531514. eCollection 2025.
6
Disproportionality Analysis and Causal Inference in Drug Safety.药物安全性中的不成比例性分析与因果推断
Pharmaceut Med. 2025 Mar;39(2):97-107. doi: 10.1007/s40290-024-00549-4. Epub 2025 Mar 4.
7
The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline.药物警戒中不成比例性分析的报告：聚焦于READUS-PV指南。
Front Pharmacol. 2024 Nov 27;15:1488725. doi: 10.3389/fphar.2024.1488725. eCollection 2024.
8
Not Just Another Reporting Guideline? Here's Why READUS-PV is a Major Step Forward.不仅仅是另一个报告指南？这就是为什么READUS-PV是向前迈出的重要一步。
Drug Saf. 2024 Jun;47(6):571-573. doi: 10.1007/s40264-024-01441-5. Epub 2024 May 8.
9
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration.《使用药物警戒中的个体病例安全报告进行药物安全性信号检测的不适当性分析报告（READUS-PV）：解释与说明》。
Drug Saf. 2024 Jun;47(6):585-599. doi: 10.1007/s40264-024-01423-7. Epub 2024 May 7.
10
Peer Review in Pharmacovigilance: Lens on Disproportionality Analysis.药物警戒中的同行评审：聚焦于不成比例性分析
Drug Saf. 2024 Jul;47(7):601-605. doi: 10.1007/s40264-024-01419-3. Epub 2024 Mar 18.

本文引用的文献

1
Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database.与药物使用相关的记忆障碍：法国药物警戒数据库中的病例/非病例研究更新。
Br J Clin Pharmacol. 2011 Dec;72(6):898-904. doi: 10.1111/j.1365-2125.2011.04009.x.
2
A potential competition bias in the detection of safety signals from spontaneous reporting databases.自发报告数据库中信号检测的潜在竞争偏倚。
Pharmacoepidemiol Drug Saf. 2010 Nov;19(11):1166-71. doi: 10.1002/pds.2022.
3
Selected control events and reporting odds ratio in signal detection methodology.信号检测方法学中的选定对照事件和报告比值比。
Pharmacoepidemiol Drug Saf. 2010 Nov;19(11):1159-65. doi: 10.1002/pds.2014.
4
Quantitative signal detection using spontaneous ADR reporting.使用自发药品不良反应报告进行定量信号检测。
Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):427-36. doi: 10.1002/pds.1742.
5
Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.安全警报对自发报告数据库中不成比例性衡量指标的影响：恶名偏见。
Drug Saf. 2007;30(10):891-8. doi: 10.2165/00002018-200730100-00007.
6
The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions.药物不良反应自发报告中不成比例性测量方法（报告比值比、比例报告率）的历史。
Pharmacoepidemiol Drug Saf. 2005 Apr;14(4):285-6. doi: 10.1002/pds.1058.
7
Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.抗HERG活性与药物性心律失常及猝死风险
Eur Heart J. 2005 Mar;26(6):590-7. doi: 10.1093/eurheartj/ehi092. Epub 2005 Jan 6.
8
Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs.使用自发药物不良反应数据库检测药物相互作用：以利尿剂和非甾体抗炎药为例
Eur J Clin Pharmacol. 2000 Dec;56(9-10):733-8. doi: 10.1007/s002280000215.
9
Non-puerperal lactation associated with antidepressant drug use.与抗抑郁药物使用相关的非产褥期泌乳
Br J Clin Pharmacol. 1997 Sep;44(3):277-81. doi: 10.1046/j.1365-2125.1997.00652.x.
10
Serum sickness-like reactions to cefaclor.头孢克洛引起的血清病样反应。
J Clin Epidemiol. 1992 Oct;45(10):1177-84. doi: 10.1016/0895-4356(92)90158-j.